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Introduction. Nowadays, four different types of influenza vaccines 
are available in Italy: trivalent (TIV), quadrivalent (QIV), MF59-
adjuvanted (aTIV) and intradermal TIV (idTIV) inactivated vaccines. 
Recently, a concept of the appropriateness (i.e. according to the age 
and risk factors) of the use of different vaccines has been established 
in Italy. We conducted a budget impact analysis of switching to a pol-
icy, in which the Italian elderly (who carry the major disease burden) 
received the available vaccines according to their age and risk profile.
Methods. A novel budget impact model was constructed with a 
time horizon of one influenza season. In the reference scenario 
the cohort of Italian elderly individuals could receive either 
available vaccine according to 2017/18 season market share. The 
alternative scenario envisaged the administration of TIV/QIV to 
people aged 65-74 years and at low risk of developing influenza-
related complications, while aTIV/idTIV were allocated to high-
risk 65-74-year-olds and all subjects aged ≥ 75 years.
Results. Switching to the alternative scenario would result in both 
significant health benefits and net budget savings. Particularly, it 
would be possible to prevent an additional 8201 cases of labora-
tory-confirmed influenza, 988 complications, 355 hospitalizations 
and 14 deaths. Despite the alternative strategy being associated 
with slightly higher vaccination costs, the total savings derived 
from fewer influenza events completely resets this increase with 
net budget savings of € 0.13 million.
Conclusions. An immunization policy in which influenza vaccines 
are administered according to the age and risk profile of Italian 
elderly individuals is advisable.
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Summary
Introduction
In Italy, influenza is still the third largest cause of in-
fectious disease-related mortality [1]; most influenza-at-
tributable deaths occur in the elderly [2, 3]. Vaccination 
remains the most important and effective public health 
measure able to dramatically reduce the large burden 
of seasonal influenza [4]. Indeed, given that the elderly 
are the most affected population, all member states of 
the European Union recommend seasonal influenza im-
munization for this particularly vulnerable group [5]. 
Both National [6] and supranational [5] authorities have 
recognized the value of influenza immunization among 
seniors and demand at least a 75% vaccination coverage 
(VC) or better still a 95% VC.
VC rates among single Italian regions are often de-
scribed as “jeopardized” [7]. This figure may be exempli-
fied by seasonal influenza VC rates among the elderly: 
in  2016/17 there was a 1.7-fold difference between re-
gions, from 37.3% in South Tyrol to 63.1% in Umbria [8]. 
In the context of the Italian fiscal federalism, the Ministry 
of Health periodically issues, following approval of the 
State-Regions Conference, National Immunization Pre-
vention Plans (the last edition for 2017–2019) aimed at 
guiding and harmonizing immunization strategies across 
the regions. Each Region then adopts its own immuniza-
tion plan [9]. Moreover, prior to the commencement of 
an influenza season, the Ministry of Health issues “Pre-
vention and Control of Influenza” recommendations for 
a given season [6, 10]. Each Region may then fully adopt 
the national recommendation or provide its own circular.
Unlike vaccines against several other diseases, the mar-
ket of influenza vaccines is significantly diverse. In the 
last 2017/18 influenza season, four different vaccine 
types were available for immunization of the elderly, 
namely, trivalent inactivated vaccines (TIVs), MF59-
adjuvanted TIV (aTIV), intradermal TIV (idTIV) and 
quadrivalent inactivated vaccines (QIV). These four 
vaccine formulations have different clinically important 
features, including age indication, route of administra-
tion, immunogenicity, vaccine effectiveness (VE), etc. 
[6, 11-13]. For instance, while TIV and QIV may be 
administered to all principal age-classes [6], aTIV and 
idTIV have been specifically developed for older adults 
in order to overcome the suppressive phenomenon of 
immunosenescence [6, 14-16].
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Procurement of influenza vaccines in Italy is based on re-
gional tenders with four separate lots for the four aforemen-
tioned vaccine types. The vaccine mix (i.e. relative procure-
ment distribution of single vaccine types) is changing con-
tinuously and partly reflects the evolving market situation 
(e.g. QIV has recently entered the market). Similarly to the 
“jeopardized” nature of influenza VC rates, the influenza 
vaccine mix is highly inhomogeneous among single re-
gions. Several factors may have contributed to this inhomo-
geneity. For example, in some regions the vaccine acquisi-
tion price may be crucial, with TIV (as the “oldest” of the 
available alternatives) being the cheapest option.
It has been recently shown [13] that all available vaccines 
are cost-effective in the elderly Italian population when 
compared with non-vaccination. However, aTIV has the 
most favorable economic profile, being a highly cost-effec-
tive strategy compared with TIV and the dominant (both in 
terms of cost-saving and effectiveness) strategy compared 
with idTIV and QIV. However, while the cost-effectiveness 
analysis allows the value comparison of different strategies, 
it cannot directly address the issues of the affordability and 
sustainability of such interventions. This is why the budget 
impact analysis (BIA) is increasingly required by reim-
bursement authorities as a part of a comprehensive eco-
nomic evaluation of a technology [17]. Here we quantified 
the impact of a “diversified” (i.e. according to the age and 
risk category) seasonal influenza offer to the Italian elderly 
population on the national budget with the ultimate goal of 
informing administrators of regional influenza vaccination 
programs about tender policies.
Methods
Model structure and basic assumptions
A novel budget impact model was built in Microsoft 
Excel (Microsoft Corporation, Redmond, WA, USA). 
The model simulates the natural history of laboratory-
confirmed influenza (LCI). Briefly, an elderly individual 
(defined here as subject aged ≥  65 years) at lower or 
higher risk of developing an influenza-related compli-
cation (see below) may be vaccinated (according to the 
current VC rate) with one of the four available influenza 
vaccines (according to the assumed market share). The 
non-vaccinated sub-cohort will develop LCI according 
to its average natural attack rate; by contrast, the vac-
cinated sub-cohort will have some reduction – according 
to the vaccine efficacy of single vaccines – in the number 
of LCI and all consecutive events. People infected with 
virus may develop a complication that, in turn, may be 
treated in either outpatient or inpatient regimens. Finally, 
the hospitalized elderly may die or survive. A simplified 
version of the model is depicted in Figure 1.
Fig. 1. A simplified decision-tree model used in the budget impact analysis.
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Time horizon and perspective
Given that both consequences of seasonal influenza 
and associated healthcare expenditure are assessable in 
a short-term period and in order to facilitate the com-
prehension of major results by all relevant stakeholders, 
the time horizon was set to one year corresponding to 
one influenza season. As recommended [17], the analy-
sis was conducted from the perspective of the National 
Healthcare Service (NHS), i.e. only direct costs were 
considered.
Target population
The latest Italian National Vaccine Prevention Plan [18] 
recommends a universal seasonal influenza vaccina-
tion for people aged ≥ 65 years. As of 2017, a total 
of 13,528,550 Italian people were aged 65 years or 
more [19]. The whole elderly cohort is not homogene-
ous with regard to different features; it, for example, is 
comprised of people with and without serious chronic 
conditions. The presence of at least one underlying se-
rious disease significantly increases the likelihood of 
developing an influenza-related complication [20, 21]. 
According to the National Institute of Statistics [22], 
44.1% of Italian ≥ 65-year-olds have at least one seri-
ous chronicity. The assumed parameter is very close to 
that used in a previous Italian economic evaluation [23]. 
Moreover, compared with elderly individuals aged 65-74 
years, those aged ≥ 75 years (51.2% of the elderly [19]) 
have significantly more pronounced features of immu-
nosenescence [24], which results in suboptimal immune 
responses to traditional influenza vaccines [14-16].
Immunization rate, current vaccine mix  
and hypothetical vaccine mix with rationale
The probability of receiving vaccination was set 
to  52.0%, which reflects the last available (season 
2016/17) official VC data among the Italian elderly [8], 
and is independent of vaccine type. 
As mentioned above, four different vaccine types 
(with four different lots in public tenders) are currently 
commercially available in Italy. The current (season 
2017/18) market share was quantified through analysis 
of allotments requested by single Italian regions. How-
ever, these estimates do not exactly reflect the vaccine 
mix among the elderly since (i) no elderly-specific 
number of doses of single vaccines requested were 
known, (ii) all four types of vaccine are routinely ad-
ministered to the elderly, (iii) and idTIV and aTIV may 
be administered only to older adults. To establish an 
elderly-specific market share we proceeded as follows. 
Given that, the Italian Ministry of Health provides data 
[8] on VC relative only to the elderly and general popu-
lations (15.1%), we first calculated a VC among people 
aged < 65 years (4.5%). We then assumed (following 
a consultation with external experts) that the off-label 
administration of idTIV and aTIV can be neglected; 
therefore, non-elderly people may receive TIV or QIV 
only. To figure out the elderly-specific market share, 
we adjusted the parameter of interest by subtracting the 
quota of TIV and QIV allocated to non-elderly indi-
viduals.
To establish a hypothetical market share, we both con-
sulted experts and analyzed the available regional poli-
cies regarding seasonal influenza immunization among 
the elderly. We found annual recommendations issued 
by the Region of Emilia-Romagna [25, 26] very com-
prehensive and in line with a recently published paper 
by Bonanni et al. [27] on the appropriateness of the 
use of different influenza vaccines available in Italy. In 
particular, in the latest Emilia-Romagna circular  [26] 
it is stated that subunit TIVs are the only available al-
ternative for young children aged 6-35 months, and 
may be eventually administered to healthy people aged 
up to 65 years. QIVs should be given to people aged 
3-65 years with chronic underlying conditions, health-
care professionals, and it is also possible to administer 
these vaccines to people aged 65-74 years without im-
munosuppressive pathologies. aTIV is recommended 
for people aged ≥  65 years especially if affected by 
underlying conditions leading to immunosuppression 
and all elderly individuals aged > 75 years. idTIV, 
which is indicated for those  ≥  60 years old, may be 
also used  – specifically due to the intradermal route 
of administration – in people with coagulopathies (that 
easily encounter hemorrhage or hematomas following 
an intramuscular injection) and those being immunized 
at home [26].
The imputation process of a hypothetical vaccine mix 
considered both the abovementioned statements from 
the latest Emilia-Romagna circular [26] and the fact that 
the elderly in low- and high-risk groups have different 
patterns of vaccination and clinical outcomes (see be-
low). Thus, at the first step we established a vaccine mix 
for the elderly at high-risk of LCI-related complications. 
Considering the Emilia-Romagna circular [26], it was 
assumed that only aTIV and idTIV should be adminis-
tered to this subpopulation in a ratio of 5.6, which re-
flects the latest tender allotment in Emilia-Romagna. To 
establish a vaccine mix for the low-risk elderly group 
(again, in order to reflect the Emilia-Romagna circu-
lar [26]), these were divided into two sub-cohorts, name-
ly 65-74 year-olds and ≥ 75 year-olds. The first sub-co-
hort could receive either TIV or QIV according to their 
current countrywide elderly-specific market share ratio 
of 0.79, while the second sub-cohort may be immunized 
only with aTIV and idTIV in the above-described ratio 
of 5.6. The current and hypothetical vaccine mixes are 
summarized in Table I.
Tab. I. Current and hypothetical vaccine mixes, by vaccine type.
Vaccine
Current elderly-specific 
vaccine mix (low risk 
and high risk), %
Alternative elderly-
specific vaccine mix 
(low risk/high risk), %
TIV 20 26/0
aTIV 40 37/85
idTIV 15 6/15
QIV 25 31/0
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Model input parameters and sources
Most input parameters relative to epidemiology, clini-
cal outcomes of LCI, and costs were adapted from our 
recent CEA [13]; these are summarized in Table II. 
Some parameters were extracted as shown in Table II, 
some were averaged in order to reflect different sea-
sons, while some were interpolated to reflect the Italian 
reality. Italy-based parameters were comprehensively 
searched and preferred providing that these were ro-
bust and nationally representative. For a detailed de-
scription of all model parameters, their strengths and 
shortcomings, readers are invited to assess a report 
by Di Pietro et al.  [13]. Briefly, considering that the 
official VC data do not distinguish between low- and 
high-risk elderly, risk-specific VCs were imputed. It 
has been establishe  [28] that compared to the Italian 
elderly at low risk of developing influenza-related 
complications those at high risk have a relative risk of 
being immunized of approximately 1.2. To establish a 
risk-category-specific VC we formulated the follow-
ing equation: (0.559 × VClow risk) + (0.441 × VChigh risk) 
= 52.0%, i.e. (0.559 × VClow risk) + (0.441 × 1.2 × VClow 
risk) = 52.0%. This equation allowed us to assume VC 
rates of 47.8% and 57.3% for the elderly at low and 
high risk, respectively.
The natural attack rate of influenza was set to 5.4%. 
This came from an imputation approach: a baseline 
meta-analytically obtained influenza-like illness (ILI) 
attack rate among the Italian elderly (16.8%) [29] 
was weighted by an average Italy-specific influenza 
virus isolation rate (32%) [30]. The assumed param-
eter resulted congruent with an estimate (5.7%) from a 
pooled analysis of placebo arms in elderly-specific ran-
domized controlled trials [31]. It was next assumed that 
approximately a third (38.6%) of the elderly with LCI 
will seek care from their general practitioners (GPs). 
This estimate is an elderly-specific average and came 
from a web-based Italian participatory surveillance 
system for influenza [32].
Tab. II. Input parameters used to populate the model (base case), by risk group.
Parameter Low-risk elderly High-risk elderly Reference
E
p
id
e
m
io
lo
g
ic
al
 a
n
d
 c
lin
ic
al
, %
Vaccination 47.8 57.3 8, 28
LCI 5.4 5.4 29, 30
Outpatient visit | LCI 38.6 38.6 32
P Bronchitis | LCI 2.69 3.46 21
P Pneumonia | LCI 1.04 1.31 21
P URTI | LCI 4.50 4.67 21
P CV complication | LCI 0.09 0.80 21
P CNS complication | LCI 0.21 0.31 21
P Renal complication | LCI 0.05 0.16 21
P Otitis media | LCI 0.21 0.15 21
P GI bleeding | LCI 0.66 0.66 21
P Hospitalization | complication 26.4 34.3 33–35
P Death | complication 3.6 3.8 21, 37
V
E
, %
TIV 58.0 38
rVE (vs TIV) of aTIV 25.0 39
rVE (vs TIV) of idTIV 16.5 40
rVE (vs TIV) of QIV 6.6 23, 41, 42
C
o
st
s,
 €
TIV price 2.11 Weighted average (regional allotments)
aTIV price 5.28 Weighted average (regional allotments)
idTIV price 5.37 Weighted average (regional allotments)
QIV price 5.80 Weighted average (regional allotments)
Vaccine administration 6.16 44
GP visit 20.66 43
Outpatient treatment of complications 
(except for otitis media)
80.0 45
Outpatient treatment of otitis media 50.0 45
Bronchitis (DRG 097) 1,832 23, 46
Pneumonia (DRG 090) 2,291 23, 46
URTI (DRG 080) 4,422 23, 46
Cardiovascular complications (weighted 
mean DRGs)
3,544 29
Renal complications (DRG 316) 3,734 23, 46
CNS complications (weighted mean DRGs) 3,507 29
Otitis media (DRG 069) 1,247 23, 46
GI bleeding (DRG 175) 2,091 23, 46
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Given the unavailability of large-scale elderly-specific 
Italian data on the consequences of LCI, these were es-
tablished by experts from the international literature. 
A large-scale UK study by Meier et al. [21] was used 
to quantify influenza-related complications among the 
elderly belonging to low- and high-risk categories. The 
probability of hospitalization following a LCI-related 
complication was interpolated from the United States 
surveillance system FluSurv-NET (elderly-specific av-
eraged data) [33] to the Italian elderly population. The 
estimated figure was then adjusted to the sensitivity of 
the polymerase chain reaction (PCR) influenza test that 
is relatively low in the elderly [34, 35]. By performing 
calculations, a total of 23,539 expected hospitalizations 
were established. It was assumed that, like in the case of 
LCI-related complications, the elderly at high risk had 
a greater probability of being hospitalized (relative risk 
vs elderly at low risk of 1.3 [21]). The resulting prob-
abilities were 26.4% and 34.3% for the elderly at low 
and high risk, respectively.
Considering the mortality following LCI, it was decided 
not to use the statistically imputed excess mortality es-
timates since it is based on a statistical imputation. In-
deed, a recent meta-regression analysis [36] highlighted 
that the statistical model selected has a significant im-
pact on the estimate and that “no average estimate of 
excess mortality could reliably be made”. Instead, we 
identified a study by Arriola et al. [37] that reported 
LCI-related mortality among non-vaccinated elderly 
being 3.8%. Given that almost all elderly in that sub-
sample had at least one underlying health condition, we 
attributed this proportion to the at risk elderly. To figure 
out the mortality rate among the elderly at low risk, we 
deflated the estimate by Arriola et al. [37] by applying a 
correction factor derived from a ratio of the probability 
of death among low- and high-risk elderly reported by 
Meier et al. [21]. However, it should be considered that 
the number of deaths was considered only in the com-
parison between alternative scenarios from the point of 
view of Public Health impact and not budgetary impact 
(i.e. the cost of death was not quantified).
A meta-analytically obtained TIV VE of 58.0% [38] was 
used. The relative (i.e. vs TIV) VE (rVE) of aTIV, idTIV 
and QIV was assumed to be 25.0%, 16.5% and 6.6%, 
respectively. While the rVE of aTIV and idTIV were 
adopted from a large-scale multi-season observational 
study [39] and robust regression modeling [40], respec-
tively, that of QIV was imputed, given the unavailability 
of VE data in the elderly. The additional benefit of the 
second B lineage strain was imputed, using a methodol-
ogy similar to previous research on the topic [23], by 
weighting the relative frequency of B virus type in the 
elderly (17.9%), average level of B lineage mismatch 
(60.1%) [23] and rVE of QIV vs TIV against the mis-
matched B lineage (35%) [41, 42].
Vaccine acquisition price is a weighted average of award-
ed prices at regional tenders. Costs relative to vaccine ad-
ministration and general GP visits derived from official 
documents [43, 44], while the ambulatory treatment of 
LCI-related complications were adapted from Marchetti 
et al. [45]. Diagnosis-related groups (DRGs) reimburse-
ment tariffs were used to establish the costs of inpatient 
treatment of complications. Most DRGs (097, 090, 080, 
316, 069 and 175) were taken directly from the current of-
ficial reimbursement documents [46]. By contrast, given 
that cardiovascular and central nervous system complica-
tions are associated with several DRGs, we used a weight-
ed average tariff estimated by Iannazzo [29].
Scenario analysis
In order to address the uncertainty, two scenario analy-
ses were conducted by changing the vaccine mix and/
or vaccine price. In particular, in the first analysis QIV 
took the whole quotum of TIV among low-risk people 
aged  65-74 years. The second scenario considered the 
same vaccine mix as the first, but with a decrease in QIV 
price by 20% (€ 4.64). Both scenarios were compared 
with the base case.
Results
Table III reports results of the base-case analysis relative 
to the most important clinical events. Over a single aver-
age influenza season, switching to the alternative sce-
nario would, approximately, prevent an additional 8,201 
cases of LCI, one thousand complications, 350 hospitali-
zations, and 14 LCI-related deaths.
From the point of view of budget implication, the alter-
native strategy would be associated with a slightly high-
er total investment (€ 1.1 million). On the other hand, 
the total savings derived from fewer influenza-related 
events completely reset (€ 1.3 million) the increase in 
vaccination campaign costs. Indeed, the alternative strat-
egy would allow a saving of approximately 0.13 million 
(Tab. IV). In summary, the base-case results suggested 
that implementation of the alternative strategy would al-
low not only for significantly fewer number of LCI and 
LCI-related events, but also significant financial savings.
If the market share of TIVs is completely absorbed by 
QIV in the low-risk 65-74 year-olds (scenario analy-
sis 1), some health-related savings would be observed 
Tab. III. Comparison of the current and alternative scenarios in terms of laboratory-confirmed influenza and following events (base-case 
results).
Parameter Current scenario Alternative scenario Difference
LCI 479,149 470,948 -8,201
Complicated LCI 49,419 48,431 -988
Hospitalizations 14,867 14,512 -355
Deaths 551 537 -14
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(Tab   V). From the economic perspective (Tab. VI), a 
slight increase (3.6% or €0.24 per person) in overall 
costs would be seen. If, on the other hand, QIV price is 
reduced by 20% (scenario 2) the overall incremental cost 
goes up by only 1% corresponding to € 0.07 per person.
Discussion
The findings reported here suggest that a shift to the alter-
native scenario would be associated with both significant 
health gains and net financial saving. The alternative sce-
nario tried to incorporate the issue on equity considering 
that the pool of elderly Italians is highly inhomogeneous 
in terms of both immune response following immuniza-
tion and risk of developing LCI-related complications. 
Such a “diversified” influenza vaccination offer finds its 
grounds in epidemiological and immunological aspects 
of ageing. Thus, the prevalence of underlying chronici-
ties increases sharply with age. If, for example, the prev-
alence of at least one serious chronic condition among 
elderly Italians aged 65-69 years is 31.7%, it growths by 
21% and 68% among people aged 70-74 and ≥ 75 years, 
respectively [22]. In turn, several chronic conditions in-
crease risk of immunosuppression [47-49]. Furthermore, 
it has been demonstrated that compared with subjects 
aged 60-75 years, in those aged > 75 years the number 
of lymphocytes falls below a critical threshold and the T 
cell receptor repertoire diminishes abruptly [24]. This is 
why the immune response to vaccination is less effica-
cious the most senior individuals and the elderly with 
underlying conditions [24, 50]; these subjects are there-
fore in need of enhanced influenza vaccines like aTIV, 
idTIV, or high-dose TIV (which is currently unavailable 
in Italy).
We also showed that a complete switch from TIV to QIV 
in the low risk elderly aged 65–74 years would be asso-
ciated with substantial health benefits and a low budget 
impact of € 0.24 per person. If, however, the price of QIV 
drops, which is highly probable, the net impact would be 
of only € 0.07 per person. This strategy should therefore 
be considered in regions with a more flexible budget. 
This scenario would also be similar to the recently pub-
lished paper by Bonanni et al. [27] on the appropriate-
ness of the use of influenza vaccines in Italy; this paper 
states that subunit TIVs should be administered to chil-
dren aged 0.5-3 years, split QIVs to subjects aged 3-70 
years at high risk (except for people aged ≥ 60 and ≥ 65 
years who due to health conditions need idTIV or aTIV, 
respectively) and aTIV/idTIV for all elderly individuals 
aged > 70 years [27].
More generally, our results confirm that the influ-
enza immunization policy adopted by Emilia-Romag-
na  [25,  26] is sound also from both public health and 
economic impact points of view. Emilia-Romagna may 
be considered as a benchmark Region in terms of both 
healthcare performance and immunization policies. The 
most recent Meridiano Sanità regional index [51] put 
Emilia Romagna at second place in the area “Effective-
ness, efficiency and appropriateness of healthcare provi-
sion”. In 2016, the Region was the first to introduce a 
mandatory character for some vaccines in order to ac-
cess educational services for young children [52]. The 
seasonal influenza coverage rate in Emilia-Romagna is 
also higher than the national average [8].
Our discussion should include the comparison of our 
findings with previous research. However, only a few 
BIAs on this topic have been conducted so far. The early 
BIA by Iannazzo [29] compared the budget impact of a 
complete switch from TIV to aTIV; the budget impact of 
the use of either vaccine was also compared with non-
Tab. IV. Comparison of the current and alternative scenarios in terms of direct costs (base-case results).
Parameter Current scenario Alternative scenario Difference
Total vaccination costs, € 77,012,493 78,131,409 +1,118,916
Total event costs, € 15,079,950 13,828,051 -1,251,899
Overall costs, € 92,092,443 91,959,460 -132,983
Tab. V. Scenario analysis: comparison of the base-case and scenarios 1 and 2 in terms of laboratory-confirmed influenza and following events.
Parameter Base-case Scenarios 1/2 Difference
LCI, N 470,948 469,019 -1,929
Complicated LCI, N 48,431 48,249 -182
Hospitalizations, N 14,512 14,464 -48
Deaths, N 537 536 -1
Tab. VI. Scenario analysis: comparison of the base-case and scenarios 1 and 2 in terms of direct costs
Parameter Base-case Scenario 1 Difference* Scenario 2 Difference*
Total vaccination costs, € 78,131,409 81,599,501 +3,468,092 79,209,359 +1,077,950
Total event costs, € 13,828,051 13,644,505 -183,546 13,644,505 -183,546
Overall costs, € 91,959,460 95,244,006 +3,284,546 92,853,864 +894,404
*Difference between the base-case and a given scenario.
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vaccination. In particular, the author established that the 
use of either vaccine would be associated with signifi-
cant reduction in the number of cases of ILI and follow-
ing events. However, compared with non-vaccination, 
the use of TIV would have produced a 4.6% increase 
(€ 50.2 million) in overall costs; while the universal use 
of aTIV among the elderly would have yielded a net sav-
ing of € 74 million. The results by Iannazzo [29] can-
not be directly compared with our findings due to dif-
ferences in model structures and several assumptions. 
First, given that, in the time frame only two alternatives 
were available, Iannazzo [29] compared the budgetary 
impact of only TIV, aTIV and no vaccination, assuming 
their universal use and therefore without establishing a 
vaccine mix. Second, the attack rate of ILI and not LCI 
were used, overestimating the economic output. Third, 
a significantly higher proportion of the elderly at high 
risk of developing complications was exploited. Fourth, 
the TIV acquisition price was mush higher (€ 3.81 vs 
€  2.25), while the relative (vs aTIV) increase in price 
was much lower (+46% vs +150%) [29].
The second more recent BIA [53] investigated the in-
troduction of QIV; the model was not elderly-specific, 
i.e. the entire Italian population was included. The in-
troduction of QIV with a market share of 9% was as-
sociated with both health benefits and some net savings 
(€  674,089; €  0.01/person). However, the increase in 
QIV market share (from 0% to 9%) was mostly deter-
mined by reduction in the market share of aTIV (from 
25% to 14%). Moreover, in that model the market share 
of TIV had a slight increase (from 49% to 52%) [54]. In 
real life, however, the increase in QIV was mostly driven 
by a progressive reduction in the quotum of TIV, while 
aTIV market share saw some increase.
Although all costs used in our model are specific to the 
Italian healthcare system, some input parameters rela-
tive to the disease natural history came from non-Italian 
sources. Indeed, it was sometimes not possible to iden-
tify robust, population-based representative and elder-
ly-specific data from Italian literature. It is likely that 
some crucial model parameters were underestimated. 
For instance, the hospitalization rate was not adjusted 
by the likelihood of influenza testing that is relatively 
low among seniors. In this regard, Reed et al. [35] have 
estimated that the number of observed influenza-related 
hospitalizations in over-65-year-olds should be inflated 
by a factor of 5.2. Given that hospitalization is a ma-
jor driver of LCI-related costs, our estimates are con-
servative. Moreover, the assumed rVE (25%) of aTIV 
vs TIV may be underestimated: it has been shown [54] 
that aTIV is more effective than TIV in preventing LCI 
among the Canadian elderly by 63%.
In conclusion, a seasonal influenza immunization policy 
targeting the elderly Italian population, in which enhanced 
vaccines (aTIV and idTIV) are administered to high-risk 
elderly individuals aged 65-74 years and all those ≥ 75 
years old, while TIV/QIV are administered to the low-
risk elderly individuals aged 65-4 years, would be associ-
ated with both substantial health benefits and net finan-
cial savings. Moreover, this strategy is more equitable and 
therefore decision-makers and other relevant stakeholders 
should consider the implementation of such age- and risk-
tailored influenza vaccination policies in their regions.
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